Regulation of prostate cancer cell proliferation by somatostatin receptor activation

Molecular and Cellular Endocrinology

Volumn 315, Issue 1-2, 2010, Pages 254-262

  Ruscica, Massimiliano ^a   Arvigo, Marica ^b   Gatto, Federico ^b   Dozio, Elena ^a   Feltrin, Daniel ^a   Culler, Michael D ^c   Minuto, Francesco ^b   Motta, Marcella ^a   Ferone, Diego ^b   Magni, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Biomeasure Inc   (United States)

Author keywords

Androgen dependent prostate cancer; Cell proliferation; IGFs system; Somatostatin analogs; Somatostatin receptor subtypes dimerization

Indexed keywords

ANGIOPEPTIN; BIM 23120; BIM 23206; BIM 23244; BIM 23296; BIM 23704; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; PROTEIN P21; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; PEPTIDES, CYCLIC; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 71849088362     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.11.006     Document Type: Article

References (54)

1. Ben-Shlomo A., Wawrowsky K.A., Proekt I., Wolkenfeld N.M., Ren S.G., Taylor J., Culler M.D., and Melmed S. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J. Biol. Chem. 280 (2005) 24011-24021
2. Birnbaum R.S., Ware J.L., and Plymate S.R. Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts. J. Endocrinol. 141 (1994) 535-540
3. Boerlin V., van der Hoek J., Beglinger C., Poon K.W., Hartmann S., Dutreix C., Kovarik J.M., Bruns C., Weckbecker G., Lewis I., Schnieper P., Hofland L.J., and Lamberts S.W. New insights on SOM230, a universal somatostatin receptor ligand. J. Endocrinol. Invest. 26 (2003) 14-16
4. Bogden A.E., Taylor J.E., Moreau J.P., and Coy D.H. Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res. 50 (1990) 2646-2650
5. Brevini T.A., Bianchi R., and Motta M. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. J. Clin. Endocrinol. Metab. 77 (1993) 626-631
6. Coy, D.H., Murphy, W.A., 1990. Linear somatostatin analogs. U.S., WO 90/12811.
7. degli Uberti, E.C., Zatelli, M.C., Culler, M.D., 2002. Method of modulating the proliferation of medullary thyroid carcinoma cells. U.S., WO 02/070555.
8. Dizeyi N., Konrad L.K., Bjartell A., Wu H., Gadaleanu V., Hansson J., Helboe L., and Abrahamsson P.A. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol. Oncol. 7 (2002) 91-98
9. Djavan B., Waldert M., Seitz C., and Marberger M. Insulin-like growth factors and prostate cancer. World J. Urol. 19 (2001) 225-233
10. Djavan B. Editorial. Prostate cancer update. BJU Int. 100 Suppl. 2 (2007) 1
11. Djordjijevic D., Zhang J., Priam M., Viollet C., Gourdji D., Kordon C., and Epelbaum J. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures. Endocrinology 139 (1998) 2272-2277
12. Erten C., Karaca B., Kucukzeybek Y., Gorumlu G., Cengiz E., Gul M.K., Atmaca H., Uzunoglu S., Karabulut B., Sanli U.A., and Uslu R. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int. 104 (2009) 107-114
13. Ferone D., Arvigo M., Semino C., Jaquet P., Saveanu A., Taylor J.E., Moreau J.P., Culler M.D., Albertelli M., Minuto F., and Barreca A. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am. J. Physiol. Endocrinol. Metab. 289 (2005) E1044-E1050
14. Figg W.D., Thibault A., Cooper M.R., Reid R., Headlee D., Dawson N., Kohler D.R., Reed E., and Sartor O. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer 75 (1995) 2159-2164
15. Gordon, T.D., Morgan, B.A., Culler, M.D., 2003. Somatostatin analogs and uses thereof. U.S., WO 03/045320.
16. Halmos G., Schally A.V., Sun B., Davis R., Bostwick D.G., and Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J. Clin. Endocrinol. Metab. 85 (2000) 2564-2571
17. Hejna M., Schmidinger M., and Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?. Ann. Oncol. 13 (2002) 653-668
18. Hofland L.J., and Lamberts S.W. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 24 (2003) 28-47
19. Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman Z.L., Friedman M., Papsidero L., Kim U., Chai L.S., Kakati S., Arya S.K., and Sandberg A.A. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 37 (1980) 115-132
20. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., and Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 43 (1983) 1809-1818
21. Kalkner K.M., Nilsson S., and Westlin J.E. [111In-DTPA-D-Phe1]-octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment: a pilot study. Anticancer Res. 18 (1998) 513-516
22. Kawada M., Inoue H., Masuda T., and Ikeda D. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res. 66 (2006) 4419-4425
23. Khan I.U., and Beck-Sickinger A.G. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med. Chem. 8 (2008) 186-199
24. Kimura N., Takamatsu N., Yaoita Y., Osamura R.Y., and Kimura N. Identification of transcriptional regulatory elements in the human somatostatin receptor sst2 promoter and regions including estrogen response element half-site for estrogen activation. J. Mol. Endocrinol. 40 (2008) 75-91
25. Krantic S., Goddard I., Saveanu A., Giannetti N., Fombonne J., Cardoso A., Jaquet P., and Enjalbert A. Novel modalities of somatostatin actions. Eur. J. Endocrinol. 151 (2004) 643-655
26. Lamberts S.W., van der Lely A.J., and Hofland L.J. New somatostatin analogs: will they fulfil old promises?. Eur. J. Endocrinol. 146 (2002) 701-705
27. Liu Z., Marquez M., Nilsson S., and Holmberg A.R. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol. Rep. 20 (2008) 151-154
28. Lo Nigro C., Maffi M., Fischel J.L., Formento P., Milano G., and Merlano M. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int. 102 (2008) 622-627
29. Maulard C., Richaud P., Droz J.P., Jessueld D., Dufour-Esquerre F., and Housset M. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother. Pharmacol. 36 (1995) 259-262
30. Nickerson T., Chang F., Lorimer D., Smeekens S.P., Sawyers C.L., and Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61 (2001) 6276-6280
31. Nilsson S., Reubi J.C., Kalkner K.M., Laissue J.A., Horisberger U., Olerud C., and Westlin J.E. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res. 55 (1995) 5805s-5810s
32. Nouel D., Gaudriault G., Houle M., Reisine T., Vincent J.P., Mazella J., and Beaudet A. Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 138 (1997) 296-306
33. Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 20 (1999) 157-198
34. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B.A., Wernicke D., and Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53 (1993) 1102-1106
35. Plonowski A., Schally A.V., Nagy A., Sun B., and Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res. 59 (1999) 1947-1953
36. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24 (2003) 389-427
37. Reubi J.C. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80 Suppl. 1 (2004) 51-56
38. Reubi J.C., Waser B., Schaer J.C., and Laissue J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28 (2001) 836-846
39. Reubi J.C., Waser B., Schaer J.C., and Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J. Clin. Endocrinol. Metab. 80 (1995) 2806-2814
40. Roddam A.W., Allen N.E., Appleby P., Key T.J., Ferrucci L., Carter H.B., Metter E.J., Chen C., Weiss N.S., Fitzpatrick A., Hsing A.W., Lacey Jr. J.V., Helzlsouer K., Rinaldi S., Riboli E., Kaaks R., Janssen J.A., Wildhagen M.F., Schröder F.H., Platz E.A., Pollak M., Giovannucci E., Schaefer C., Quesenberry Jr. C.P., Vogelman J.H., Severi G., English D.R., Giles G.G., Stattin P., Hallmans G., Johansson M., Chan J.M., Gann P., Oliver S.E., Holly J.M., Donovan J., Meyer F., Bairati I., and Galan P. Insulin-like growth factors. Their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann. Intern. Med. 149 (2008) 461-488
41. Ruscica M., Dozio E., Boghossian S., Bovo G., Martos Riano V., Motta M., and Magni P. Activation of the Y1 receptor by neuropeptide y regulates the growth of prostate cancer cells. Endocrinology 147 (2006) 1466-1473
42. Russell P.J., Bennett S., and Stricker P. Growth factor involvement in progression of prostate cancer. Clin. Chem. 44 (1998) 705-723
43. Sarret P., Nouel D., Dal Farra C., Vincent J.P., Beaudet A., and Mazella J. Receptor-mediated internalization is critical for the inhibition of the expression of growth hormone by somatostatin in the pituitary cell line AtT-20. J. Biol. Chem. 274 (1999) 19294-19300
44. Saveanu A., Gunz G., Dufour H., Caron P., Fina F., Ouafik L., Culler M.D., Moreau J.P., Enjalbert A., and Jaquet P. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J. Clin. Endocrinol. Metab. 86 (2001) 140-145
45. Sharif N., Gendron L., Wowchuk J., Sarret P., Mazella J., Beaudet A., and Stroh T. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 148 (2007) 2095-2105
46. Sinisi A.A., Bellastella A., Prezioso D., Nicchio M.R., Lotti T., Salvatore M., and Pasquali D. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. J. Clin. Endocrinol. Metab. 82 (1997) 2566-2569
47. Taylor J.E., Theveniau M.A., Bashirzadeh R., Reisine T., and Eden P.A. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 15 (1994) 1229-1236
48. Tejeda M., Gaal D., Hullan L., Hegymegi-Barakonyi B., and Keri G. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. Anticancer Res. 26 (2006) 3477-3483
49. Thakur M.L., Kolan H., Li J., Wiaderkiewicz R., Pallela V.R., Duggaraju R., and Schally A.V. Radiolabeled somatostatin analogs in prostate cancer. Nucl. Med. Biol. 24 (1997) 105-113
50. Tressel T.J., Tatsuno G.P., Spratt K., and Sommer A. Purification and characterization of human recombinant insulin-like growth factor binding protein 3 expressed in Chinese hamster ovary cells. Biochem. Biophys. Res. Commun. 178 (1991) 625-633
51. Viguerie N., Esteve J.P., Susini C., Logsdon C.D., Vaysse N., and Ribet A. Dexamethasone effects on somatostatin receptors in pancreatic acinar AR4-2J cells. Biochem. Biophys. Res. Commun. 147 (1987) 942-948
52. Visser-Wisselaar H.A., Hofland L.J., van Uffelen C.J., van Koetsveld P.M., and Lamberts S.W. Somatostatin receptor manipulation. Digestion 57 Suppl. 1 (1996) 7-10
53. Zapata P.D., Ropero R.M., Valencia A.M., Buscail L., Lopez J.I., Martin-Orozco R.M., Prieto J.C., Angulo J., Susini C., Lopez-Ruiz P., and Colas B. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J. Clin. Endocrinol. Metab. 87 (2002) 915-926
54. Zatelli M.C., Tagliati F., Taylor J.E., Rossi R., Culler M.D., and degli Uberti E.C. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J. Clin. Endocrinol. Metab. 86 (2001) 2161-2169